Recently published results of the analysis of the two largest studies of Plavix showed it permanent advantage in all categories of risk. The studies CURE and CAPRIE showed the advantage of Plavix in patients with low, medium and high risk of ischemic disorders.

CURE1 (Clopidgorel in Unstable Angina to Prevent Recurrent Events) study, conducted by the stratification of the risk factors of thrombosis in myocardial infarction (TIMI) and published in the journal Circulation3, found that Plavix (versus placebo) in combination with standard therapy that included aspirin, as shown in the study of CURE, always gave the best results in patients with acute coronary syndrome (ACS) without ST segment elevation in the groups of low, medium or high risk.
» Read more: Plavix – CURE study and its analysis

Atherosclerosis and atherothrombosis (acute thrombosis that develops in the presence of atherosclerosis) are the main pathological processes underlying the development of ischemic stroke (IS), coronary heart disease (CHD) and peripheral arterial lesions.

These processes have become the leading cause of death and disability in industrialized countries. According to statistical to 2020 deaths from atherothrombosis complications can reach 25 million cases per year.
The CAPRIE study remains the only antiplatelet drugs, for which there is evidence of advantages over aspirin to influence the risk of such serious events as cardiac death, MI, and AI. This drug is Plavix. » Read more: Plavix – preventing strokes